secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ultragenyx Pharmaceutical Inc. (RARE)
CIK:        0001515673
Form:       8-K
Filed at:   2023-02-16T23:59:59+00:00
Accession:  0000950170-23-003048
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ultragenyx reports FY2022 net loss $707M, revenue $363M; guides 2023 rev $425-450M
--------------------------------------------------------------------------------

- FY2022 total revenue $363.3M (+3% YoY) from $351.4M in 2021.
- Net loss $707.4M ($10.12/sh) vs $454.0M ($6.70) in 2021, driven by higher R&D and acquired IP.
- Crysvita revenue $279.4M, Dojolvi $55.6M, Mepsevii $20.6M; cash $896.7M at year-end.
- 2023 guidance: total rev $425-450M; Crysvita $325-340M; Dojolvi $65-75M; net cash use <$400M.
- Q4 net loss $151.8M ($2.16/sh) vs $122.5M ($1.79) in Q4 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1515673/000095017023003048/0000950170-23-003048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1515673/000095017023003048/rare-20230216.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-003048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer